They decided to put the Phase 3 Abssi trial on the back burner since at the current share price they believe the dilution would be excessive. I think NR was counting on management to bite the bullet and pull the trigger on a large capital raise. (Aspire or a one time Private placement). It would have most likely had a short term negative impact (good re-entry opportunity). It appears now the plan is to do a phase 2b with Prurisol and leverage that into a partnership that would more than pay for the Phase 3 Brilacidin trial with no dilution and no share price drop. In the meantime B-OM and B-UP and Kevetrin can be fleshed out.